Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                    
 
Home      About      Team      Clients      Publications      Downloads      News      Contact            

Testimonials
  I like the insights gained from Bioscience Valuation's thorough assessments that allow me to support my decisions with well-founded, rational arguments.

Dr. Axel Wiest, COO R&D, Merck-Serono

 

Core Services
  Financial Valuation
  Commercial Assessment &
Pharmacoeconomics

  R&D Risk Analysis &
Productivity Increase

  Portfolio Management
  Investment Decisions
  Partnering / Licensing
  Corporate Finance / M&A

Special Expertise
  Economic Modeling
of Healthcare Systems

  Assessing the Economics
of Personalized Medicine

Comprehensive Support
  Corporate Partnership Program

Products
  Market Model
  R&D Risk Model
  Valuation Model

Core Services - Commercial Assessment

Bioscience Valuation's Commercial Assessment covers
  • in-depth analysis of disease market, standard of care and medical need,
  • definition of target product profile (TPP),
  • forecast of incidence and prevalence,
  • detailed analysis of competitors (launched and in development),
  • a pharmacoeconomic assessment,
  • determination of a product's optimal price range and likely market share,
  • if ordered, primary market research,
  • sales forecast until patent expiry.
Core Services - Pharmacoeconomics

An early Pharmacoeconomic Assessment

  • determines a drug's incremental cost - effectiveness ratio (ICER) based on its TPP,
  • shows whether a TPP needs improvement to ensure cost - effectiveness,
  • supports management in determining a drug's market price that will likely get reimbursed.

Case:
A 'top 20' multinational pharmaceutical company asked us to perform commercial assessments for their in-licensing candidates. The client expects comprehensive analyses, adhering to the company's highest quality standards.

Our assessments provide the expected analysis that frees up the client's resources to focus on decision-making and internal communications.